Alcon initiated with a Buy at Mizuho

Mizuho analyst Anthony Petrone initiated coverage of Alcon with a Buy rating and $85 price target. The analyst cites Alcon’s lead positioning in global eye care segments, "which can act as a recession hedge," and its "long global runway" for AT-IOL product cycles for the Buy rating. He sees upside potential from a growing pharmaceutical presence following the company’s recent acquisition of Aeri Pharmaceuticals.